Pluri Inc.
PLURNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PLUR. That does not mean none is planned.
Get an email about PLUR's next catalysts
Track Pluri (PLUR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
WebsiteNo drugs found in this phase.
Frequently asked questions
When is Pluri Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Pluri Inc. (PLUR) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track PLUR biotech catalysts?β
Add PLUR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pluri Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
